OptiNose raises $138M in IPO

OptiNose Inc. (NASDAQ:OPTN) raised $138 million through the sale of 8.6 million shares at $16 in an IPO underwritten by Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets. The price was at the midpoint of OptiNose's proposed $15-$17 range, and the company sold more than the proposed 6.3 million shares. The figures include the sale of a 1.1 million share overallotment on Oct. 17.

In September, FDA approved OptiNose's Xhance fluticasone propionate nasal spray to treat nasal polyps. The company is now aiming to use its patented Exhalation Delivery Systems (EDS) in a "nose-to-brain" application to treat neurologic orphan diseases...